Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 4/20 | 0.47 |
| ▸ | PLK1 | P53350 | 5/20 | 0.47 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | NEK2 | P51955 | 3/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2488261 | 0.90 | PLK1 (0.47) | CHEK2PLK1PLK3GPR119NEK2 | |
| SCHEMBL2538229 | 0.90 | PLK1 (0.57) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL2537200 | 0.86 | PLK1 (0.46) | CHEK2PLK1PLK3NEK2PIK3CD | |
| SCHEMBL2539260 | 0.82 | PLK1 (0.42) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL2538071 | 0.81 | PLK1 (0.43) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL2540373 | 0.80 | PLK1 (0.50) | CHEK2PLK1PLK3PIM1 | |
| SCHEMBL2491218 | 0.79 | PLK1 (0.44) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL2539045 | 0.79 | PLK1 (0.59) | CHEK2PLK1PLK3NEK2PIK3CD | |
| SCHEMBL2536134 | 0.79 | PLK1 (0.55) | CHEK2PLK1PLK3NEK2 | |
| SCHEMBL2541119 | 0.79 | MEN1 (0.45) | PLK1PLK3NEK2PIK3CDNUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379543-A2 | THIAZOLYL-BENZIMIDAZOLES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2010121675-A2 | THIAZOLYL-BENZIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | CHEK2 2255/4885PLK1 2782/4885PLK3 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.